

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3920170

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AKTIESELSKABET AF 30. APRIL 2003	04/15/2011
RECEIVING PARTY DATA	
Name:	LEO LABORATORIES LIMITED
Street Address:	285 CASHEL ROAD, CRUMLIN
City:	DUBLIN
State/Country:	IRELAND
Postal Code:	12
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15163410
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(212) 641-2279
Email:	mwhite@fr.com
Correspondent Name:	TONY ZHANG
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	42764-0004011
NAME OF SUBMITTER:	MARYANN WHITE
SIGNATURE:	/Maryann White/
DATE SIGNED:	06/15/2016
Total Attachments: 16	
source=AssignmentAktieselskabetLEO#page1.tif	
source=AssignmentAktieselskabetLEO#page2.tif	
source=AssignmentAktieselskabetLEO#page3.tif	
source=AssignmentAktieselskabetLEO#page4.tif	
source=AssignmentAktieselskabetLEO#page5.tif	

source=AssignmentAktieselskabetLEO#page6.tif
source=AssignmentAktieselskabetLEO#page7.tif
source=AssignmentAktieselskabetLEO#page8.tif
source=AssignmentAktieselskabetLEO#page9.tif
source=AssignmentAktieselskabetLEO#page10.tif
source=AssignmentAktieselskabetLEO#page11.tif
source=AssignmentAktieselskabetLEO#page12.tif
source=AssignmentAktieselskabetLEO#page13.tif
source=AssignmentAktieselskabetLEO#page14.tif
source=AssignmentAktieselskabetLEO#page15.tif
source=AssignmentAktieselskabetLEO#page16.tif

FINAL
15 April 2011

DATED 15th April 2011

AKTIESELSKABET AF 30. APRIL 2003.

Assignor

and

LEO LABORATORIES LIMITED

Assignee

DEED OF ASSIGNMENT

A&L Goodbody

FINAL

TABLE OF CONTENTS

1. Interpretation 2
2. Assignment 3
3. CONSIDERATION 3
4. WARRANTIES 4
5. VAT & TAX 4
6. Further Assurance 4
7. Waiver 4
8. Entire Agreement 4
9. Variation 5
10. Severance 5
11. Counterparts 5
12. Notices 5
13. Governing Law and Jurisdiction 6
Schedule 1 7

FINAL 15 April 2011

THIS AGREEMENT is dated 15th April 2011

BETWEEN:

1. **AKTIESELSKABET AF 30. APRIL 2003** incorporated and registered in Denmark with company number 27159133 whose registered office is at Industriparken 55, 2700 Bellerup, Denmark (Assignor); and
2. **LEO LABORATORIES LIMITED** incorporated and registered in Ireland with company number 16085 whose registered office is at 286 Cashel Road, Crumlin, Dublin 2, Ireland (Assignee).

RECITALS:

1. The Assignor has certain rights in the Patents (as defined below) pursuant to:
 1. the Deed of Assignment between the Assignor and Peplin Research Pty. Ltd. (as trustee of the Peplin Unit Trust) dated [xxx]; and
 2. the Deed of Assignment between the Assignor and Peplin Ireland Limited dated [xxx],
(together the "Head Deeds of Assignment").
2. The Assignor has agreed to assign all of its rights referred to at (A) above to the Assignee on the terms set out in this Deed of Assignment.

IT IS AGREED:

1. INTERPRETATION

- 1.1. The definitions and rules of interpretation in this clause apply in this agreement.

Assigned Rights means all of the Assignor's rights pertaining to the Patents granted under the Head Deeds of Assignment.

Business Day means any day on which banks are generally open for business in Dublin, excluding Saturdays and Sundays.

Effective Date means 1 January 2011.

Patents mean the patents and the applications the particulars of which are set out in Schedule 1.

VAT means the value added tax imposed in any member state of the European Union pursuant to Council Directive (EC) 2006/112 on the common system of value added tax and national legislation implementing that Directive or any predecessor to it, or supplemental to that Directive, or any similar tax which may be substituted for or levied in addition to it or any value added, sales, turnover or similar tax imposed in any country that is not a member of the European Union.

- 1.2. Clause and schedule headings shall not affect the interpretation of this agreement.
- 1.3. The schedules form part of this agreement and shall have effect as if set out in full in the body of this agreement. Any reference to this agreement includes the Schedules.

- 1.4. References to clauses and schedules are to the clauses and schedules of this agreement.
- 1.5. Unless the context otherwise requires, words in the singular include the plural and in the plural include the singular.
- 1.6. Unless the context otherwise requires, a reference to one gender shall include a reference to the other genders.
- 1.7. A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time provided that, as between the parties, no such amendment, extension or re-enactment shall apply for the purposes of this agreement to the extent that it would impose any new or extended obligation, liability or restriction on, or otherwise adversely affect the rights of, any party. This clause does not, however, apply in relation to taxation.
- 1.8. A reference to a statute or statutory provision shall include any subordinate legislation made from time to time under that statute or statutory provision.
- 1.9. Writing or written includes faxes but not e-mail.
- 1.10. Any words following the terms including, include, in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.
- 1.11. A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person's legal and personal representatives, successors and permitted assigns.

2. ASSIGNMENT

- 2.1. In consideration of:
 - (the "Consideration"):
- 2.1.1. the Assignor assigns and transfers all of its rights, obligations, title, interest and benefit in and to the Assigned Rights to the Assignee. The Assignee shall enjoy all the rights and benefits of the Assignor and shall perform all the Assignor's obligations in respect of the Assigned Rights, and all references to the Assignor in the Assigned Rights shall be read and construed as references to the Assignee; and
- 2.1.2. the Assigned Rights shall be deemed to have transferred in accordance with the provisions of this Deed of Assignment as of the Effective Date. The transfer of the Assigned Rights occurs immediately upon execution of this Deed of Assignment. However, the parties agree that as between themselves the parties will treat the transfer as having occurred on The Effective Date is 1 January 2011.

4. **WARRANTIES**

4.1. The Assignor warrants that it:

- 4.1.1. has authority to enter into this Deed of Assignment and to assign the Assigned Rights in accordance with the provisions of this Deed of Assignment;
- 4.1.2. has not assigned or otherwise transferred any of the Assigned Rights to any other person or entity; and
- 4.1.3. the Assigned Rights are not subject to any mortgage, pledge, lien, charge or other encumbrance.

6. **FURTHER ASSURANCE**

The Assignor shall, at the Assignor's cost, perform (or procure the performance of) all further reasonable acts and things, and execute and deliver or procure the execution or delivery of all further documents, required by law or which the Assignee reasonably requests, to vest in the Assignee the full benefit of the right, title and interest assigned to the Assignee under this Deed of Assignment.

8. **ENTIRE AGREEMENT**

8.1. This agreement constitutes the whole agreement between the parties and supersedes all previous agreements between the parties relating to its subject matter.

9. **VARIATION**

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).

11. **COUNTERPARTS**

This Agreement may be executed in any number of counterparts, and by the several parties to it on separate counterparts, each of which when so executed will constitute an original but all of which together will evidence the same agreement.

✓

IN WITNESS whereof this agreement has been duly executed as a deed by the parties on the date set out at the beginning of this Agreement.

SCHEDULE 1

PATENTS

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Anti-cancer compounds	Australia	87217/88	19-Aug-88	738230	08-Nov-01	Granted
Anti-cancer compounds - I	Australia	48118/01	30-May-01	760624	07-Nov-02	Granted
Anti-cancer compounds - II	Australia	48117/01	30-May-01	748545	19-Sep-02	Granted
Anti-cancer compounds - III	Australia	48118/01	30-May-01	760626	07-Nov-02	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Austria	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Belgium	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Compounds present in plants, composition comprising a compound, method of treatment of cancer, method of inhibiting and stimulating the activity of neoplastic cells, method of preventing or alleviating damage to the skin and use of a compound and composition	Brazil	P19811327.5	19-Aug-88			Under examination - prosecution suspended
Anti-cancer compounds	Canada	2301082	19-Aug-88	2301082	03-Feb-89	Granted
Anti-cancer compounds	China	88807751.5	19-Aug-88			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Cyprus	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Denmark	n/a	19-Aug-88	1015413	04-Jun-88	Granted
Use of an ingenane compound for the manufacture of a medicament for the	Europe	98936534.9	19-Aug-88	1015413	04-Jun-88	Granted

Patent Title	Country	App. No.	Publ. Date	Publ. No.	Publ. Date	Status
treatment of cancer						
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Finland	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	France	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Germany	68839586.7	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Greece	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Anti-cancer compounds	Hungary	P0004262	18-Aug-98			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Ireland	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Italy	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Anti-cancer compounds	Japan	2000-509681	18-Aug-98			Under examination
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Luxembourg	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Monaco	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Netherlands	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Portugal		18-Aug-98	1015413	04-Jun-98	Granted
Anti-cancer compounds	Singapore	200006609.A	18-Aug-98	71228	12-Mar-92	Granted
Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer	Spain	n/a	18-Aug-98	1015413	04-Jun-98	Granted
Use of an ingenane compound for the	Sweden	n/a	18-Aug-98	1015413	04-Jun-98	Granted

Category	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
manufacture of a medicament for the treatment of cancer						
Use of an Inganano compound for the manufacture of a medicament for the treatment of cancer	Switzerland	n/a	19-Aug-98	1015413	04-Jun-05	Granted
Use of an Inganano compound for the manufacture of a medicament for the treatment of cancer	United Kingdom	n/a	19-Aug-98	1015413	04-Jun-05	Granted
Anti-cancer compounds	USA	00/486169	19-Aug-98	6432452	13-Aug-02	Granted
Anti-cancer compounds	USA	00/585178	21-Jun-01	6787181	07-Sep-04	Granted
Methods for stimulating the immune system	USA	00/589997	21-Jun-01	6544013	18-Jan-05	Granted
Anti-cancer compounds	USA	10/892811	22-Jul-04	7410858	12-Aug-08	Granted
Therapeutic agents - I	Australia	93881/01	07-Jun-01	752182	23-Jan-03	Granted
Methods for the treatment or prophylaxis of an inflammatory condition and for the immunoprotection of a subject, composition, computer program product, process for separating macrocyclic diisoprenes from a biomass and use of a chemical agent or derivative or chemical analogues thereof	Brazil	PI0111423.9	07-Jun-01			Pending - request for examination filed
Therapeutic agents - I	Canada	2411642	07-Jun-01			Under examination
Therapeutic agents - I	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01937872.8	07-Jun-01			Under examination
Therapeutic agents - I	Japan	2002-301455	07-Jun-01			Pending - request for examination filed
Therapeutic agents - I	New Zealand	522425	07-Jun-01	633425	09-Sep-04	Granted
Therapeutic agents - I	USA	10/315286	07-Jun-01	7448492	11-Nov-08	Granted
Therapeutic agents - II	Australia	63862/01	07-Jun-01	752435	23-Jan-03	Granted
A method for the treatment or prophylaxis of an inflammatory condition, of immunoprotection and immunopotentiation of a subject, a composition, a computer and a computer program product	Brazil	PI0111458.1	07-Jun-01			Pending - request for examination filed
Therapeutic agents - II	Canada	2411698	07-Jun-01			Under examination filed

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Therapeutic agents - II	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01937873.8	07-Jun-01			Under examination
Therapeutic agents - II	Japan	2002-501455	07-Jun-01			Pending - request for examination filed
Therapeutic agents - II	New Zealand	522428	07-Jun-01	522428	09-Sep-04	Granted
Macrocyclic diisopanes for treating conditions associated with protein kinase C	USA	10/315,318	07-Jun-01			Accepted
Macrocyclic diisopanes for treating conditions associated with protein kinase C	USA	12/643,087	19-Aug-09			Pending
Therapeutic agents - III	Australia	7073201	07-Jun-01	748542	19-Sep-02	Granted
Methods for the treatment or prophylaxis of condition or disorder related to PKC, for modulating the expression of genetic sequence and for stimulating the activation or function of a promoter, computer and computer program product	Brazil	PI0111376.0	07-Jun-01			Pending - request for examination filed
Therapeutic agents - III	Canada	2411726	07-Jun-01			Pending - request for examination filed
Therapeutic agents - III	Europe (designating AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)	01949015.8	07-Jun-01			Under examination
Therapeutic agents - III	Japan	2002-501454	07-Jun-01			Pending - request for examination filed
Therapeutic agents - III	New Zealand	522427	07-Jun-01	522427	09-Sep-04	Granted
Treatment of prostate cancer	Australia	70493/01	07-Aug-01	764778	08-Mar-03	Granted
Treatment of prostate cancer	Canada	2418784	07-Aug-01			Under examination
Treatment of prostate cancer	Europe (designating	01957828.8	07-Aug-01			Under examination

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
Treatment of prostate cancer	Japan	2002-517078	07-Aug-01			Pending - request for examination filed
Treatment of prostate cancer	New Zealand	524082	07-Aug-01	524082	11-Nov-04	Granted
Treatment of prostate cancer	USA	11/324567	03-Jan-06	7378446	27-May-08	Granted
Treatment of solid cancers	Australia	2005316185	02-Dec-05			Pending - request for examination filed
Treatment of solid cancers	Canada	2689992	02-Dec-05			Pending - request for examination due 02-Dec-10
Treatment of solid cancers	Europe (designating AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)	05813662.3	02-Dec-06			Pending - request for examination filed
Treatment of solid cancers	New Zealand	554710	02-Dec-05			Accepted
Treatment of solid cancers	New Zealand	683167	05-Feb-10			Under examination
Treatment of solid cancers	USA	11/792384	02-Dec-05			Under examination
Methods for wound healing	Australia	2005317523	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Brazil	PI0618928.1	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Canada	2620999	25-Nov-08			Pending - request for examination due 24-Nov-11
Methods for wound healing	China	200980051033.9	25-Nov-08			Pending - request for examination filed
Methods for wound healing	Europe (designating AT, BE, BG, CH, CY, CZ,	05817637.1	25-Nov-08			Under examination

Patent Title	Country	Application No.	Filing Date	Grant No.	Patent Date	Status
	DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)					
Methods for wound healing	Indonesia	W-06200601366	25-Nov-06			Pending - request for examination filed
Methods for wound healing	Japan	2009-541560	25-Nov-06			Pending - request for examination filed
Methods for wound healing	New Zealand	598160	25-Nov-06			Under examination
Methods for wound healing	Philippines	1-2008-501180	26-Nov-06			Pending
Methods for wound healing	Singapore	200803560.1	26-Nov-06			Under examination
Methods for wound healing	South Korea	10-2008-7014376	26-Nov-06			Pending - request for examination due 26-Nov-11
Methods for wound healing	USA	12/094,713	25-Nov-06			Pending
Methods for wound healing	Vietnam	1-2008-01664	26-Nov-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Australia	2008326244	18-Dec-06			Pending - request for examination filed
Therapeutic formulations	Brazil	PI0610919.4	18-Dec-06			Pending - request for examination filed
Therapeutic formulations comprising ingenol-3-angelate	Canada	2634073	10-Dec-06			Pending - request for examination due 10-Dec-11
Therapeutic formulations comprising ingenol-3-angelate	Eurasia	200870083	18-Dec-06			Under examination
Therapeutic formulations comprising ingenol-3-angelate	Europe (designating AT, BE, BG, CY, CZ, DK, EE, FI, FR, DE, GR, HU, IE, IT, LV, LT, LU, MC, NL, PO, PT, IE, RO, SK, SI, ES, SE, GR, TR, GB, AL, BA, HR, MG, RS, Kosovo)	06620561.0	18-Dec-06			Under examination
Therapeutic formulations	India	68070ELNP/2006	18-Dec-06			Pending - request for examination filed

Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Therapeutic formulations comprising Ingenol-3-angelate	Israel	192221	18-Dec-08			Under examination
Therapeutic formulations comprising Ingenol-3-angelate	Japan	2008-545103	18-Dec-08			Pending - request for examination filed
Therapeutic formulations	Mexico	MX/2008/007685	18-Dec-08			Pending
Therapeutic formulations	New Zealand	589197	18-Dec-08			Under examination
Therapeutic formulations comprising Ingenol-3-angelate	Norway	20083150	18-Dec-08			Pending
Therapeutic formulations comprising Ingenol-3-angelate	Singapore	20084454-B	18-Dec-08			Accepted
Therapeutic formulations	South Korea	10-2008-7017264	18-Dec-08			Pending - request for examination due 18-Dec-11
Therapeutic formulations comprising Ingenol-3-angelate	South Africa	2008/5187	18-Dec-08	2008/06187	29-Apr-09	Granted
Therapeutic formulations comprising Ingenol-3-angelate	USA	12/087358	18-Dec-08			Under examination
Therapeutic formulations	Vietnam	1-2008-01554	18-Dec-08			Pending
Treatment of virally induced lesions	Australia	2008243705	30-Apr-08			Pending
Treatment of virally induced lesions	Brazil	PI0810802-4	30-Apr-08			Pending
Treatment of virally induced lesions	Canada	288473	30-Apr-08			Pending
Treatment of virally induced lesions	China	200880019913.2	30-Apr-08			Pending
Treatment of virally induced lesions	Europe (Designating AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, NO, PO, PT, RO, SE, SI, SK, TR, Serbia-Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Serbia)	087334223	30-Apr-08			Pending
Treatment of virally induced lesions	Hong Kong	10102512.3	10-Mar-10			Pending
Treatment of virally induced lesions	Indonesia	W-00200993038	30-Apr-08			Pending
Treatment of virally induced lesions	Israel	291798	30-Apr-08			Pending


Patent Title	Country	Application No.	Filing Date	Patent No.	Patent Date	Status
Treatment of virally induced lesions	Japan	2010-504384	30-Apr-08			Pending
Treatment of virally induced lesions	Malaysia	FI20094667	30-Apr-08			Pending
Treatment of virally induced lesions	Mexico	MX/a/2009/011885	30-Apr-08			Pending
Treatment of virally induced lesions	New Zealand	588702	30-Apr-08			Pending
Treatment of virally induced lesions	Philippines	1-2009-502059	30-Apr-08			Pending
Treatment of virally induced lesions	Russian Federation	2009144100	30-Apr-08			Under examination
Treatment of virally induced lesions	Singapore	200907154-9	30-Apr-08			Pending
Treatment of virally induced lesions	South Africa	2009/07574	30-Apr-08			Pending
Treatment of virally induced lesions	South Korea	10-2009-7024681	30-Apr-08			Pending
Treatment of virally induced lesions	Ukraine	200912128	30-Apr-08			Pending
Treatment of virally induced lesions	USA	12/598,102	30-Apr-08			Pending
Treatment of virally induced lesions	Vietnam	1-2009-02622	30-Apr-08			Under examination
Skin treatment	International	PCT/AU2010/000152	12-Feb-10			Pending - Demand due 13-Dec-10 NFP due 13-Aug-11

Neostil/Osteostereon portfolio

Patent family: inhibitors of proteasomal activity for stimulating bone and hair growth

Patent family: stimulation of hair growth by ginkgo biloba flavonoids

Signed by and on behalf of
Aktieselskabet af 30. April 2003
and delivered as a Deed:



Witness Name



Witness Signature




Gitte P. Aabo, Chairman



Nina Sølvén Henning, Director


GIVEN under the Common Seal of
LEO Laboratories Limited
affixed hereto and delivered as a Deed:




Witness Name



Witness Signature



Gitte P. Aabo, Director



John Møhlbye, Director